Skip to main content

Table 4 Outcome in the study completers after 6 weeks of NIV

From: Impact of High-Intensity-NIV on the heart in stable COPD: a randomised cross-over pilot study

Variable

Order

Baseline

LI-NIV

HI-NIV

Treatment effect HI vs. LI

Mean (95% CI)

P

Change in CO, % of baseline

LIHI

 

−7.8 ± 14.9

3.2 ± 19.2

−8.5% (−27 to 10%)

0.33

 

HILI

 

17.7 ± 34.6

−10.3 ± 24.8

  

CO, L/min

LIHI

5.8 ± 1.1

5.3 ± 1.1

5.9 ± 1.2

−0.38 (−1.31 to 0.56)

0.39

 

HILI

5.1 ± 0.7

5.9 ± 1.1

4.5 ± 1.1

  

NTproBNP,pg/ml##

LIHI

177 (117–317)

113 (63–197)

158 (67–208)

37 (−26 to 101)

0.22

 

HILI

215 (61–469)

199 (91–430)

158 (88–620)

  

PaCO2, day, kPa

LIHI

6.7 ± 0.7

6.3 ± 0.7

6.1 ± 0.8*

−2.8 (−6.6 to 1.0)

0.13

 

HILI

7.0 ± 1.1

6.6 ± 0.7

6.0 ± 0.7*

  

FEV1, L

LIHI

0.72 ± 0.14

0.79 ± 0.20*

0.75 ± 0.21*

−0.00 (−0.11 to 0.10)

0.93

 

HILI

0.95 ± 0.55

1.10 ± 0.63*

1.13 ± 0.63*

  

SRI-SS

LIHI

43.3 ± 20.2

52.2 ± 19.7*

49.8 ± 20.8*

−2.9 (−8.0 to 2.0)

0.22

 

HILI

45.2 ± 13.6

55.7 ± 8.4*

52.6 ± 9.9*

  
  1. Results are presented for the patients that followed the HILI order (HILI) and the LIHI order (LIHI) seperately. Data are presented as mean ± SD#, median (IQR)## or mean (95% CI). * P < 0.05 compared to baseline value
  2. CO cardiac output, NT-proBNP N-terminal brain natriuretic peptide, PaCO 2 partial arterial carbon dioxide pressure (kilopascal (kPa)), FEV 1 forced expiratory volume in 1 s, SRI-SS severe respiratory insufficiency questionnaire summary score